Illumina helped the digital PCR technology developer secure fresh convertible bond and loan financing that will be used for international expansion and the further development of its platform.

France-based DNA quantification technology developer Stilla Technologies has raised €31.3m ($35m) in debt and convertible bond financing from investors including Illumina Ventures, the corporate venturing arm of genomics technology producer Illumina. The round also featured BNP Paribas Développement, a subsidiary of financial services firm BNP Paribas, as well as LBO France, Eurazeo, Kurma Partners, TusPark…

The rest of this content is only accessible to Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.